Travere Therapeutics, Inc. Expected to Earn FY2025 Earnings of ($1.80) Per Share (NASDAQ:TVTX)

Travere Therapeutics, Inc. (NASDAQ:TVTX) – HC Wainwright cut their FY2025 EPS estimates for shares of Travere Therapeutics in a report released on Wednesday, April 24th. HC Wainwright analyst E. Arce now anticipates that the company will post earnings per share of ($1.80) for the year, down from their previous forecast of ($1.71). HC Wainwright has a “Buy” rating and a $19.00 price target on the stock. The consensus estimate for Travere Therapeutics’ current full-year earnings is ($3.10) per share. HC Wainwright also issued estimates for Travere Therapeutics’ FY2026 earnings at $0.20 EPS and FY2027 earnings at $1.98 EPS.

Travere Therapeutics (NASDAQ:TVTX) last released its quarterly earnings data on Thursday, February 15th. The company reported ($1.16) earnings per share for the quarter, beating the consensus estimate of ($1.27) by $0.11. The company had revenue of $45.06 million during the quarter, compared to analyst estimates of $41.25 million. Travere Therapeutics had a negative net margin of 56.02% and a negative return on equity of 177.97%.

A number of other research analysts have also weighed in on the company. Wedbush reissued an “outperform” rating and issued a $13.00 price objective on shares of Travere Therapeutics in a report on Wednesday, April 17th. Guggenheim restated a “neutral” rating on shares of Travere Therapeutics in a research note on Wednesday, March 27th. Piper Sandler raised their price objective on shares of Travere Therapeutics from $10.00 to $11.00 and gave the stock a “neutral” rating in a report on Thursday, January 18th. Finally, Wells Fargo & Company upped their price target on shares of Travere Therapeutics from $8.00 to $9.00 and gave the stock an “equal weight” rating in a report on Friday, February 16th. Six research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $18.00.

Travere Therapeutics Trading Up 1.7 %

TVTX stock traded up $0.09 on Friday, reaching $5.48. The company’s stock had a trading volume of 95,149 shares, compared to its average volume of 1,253,837. Travere Therapeutics has a 12-month low of $5.12 and a 12-month high of $22.75. The business has a fifty day simple moving average of $7.34 and a two-hundred day simple moving average of $7.66. The firm has a market cap of $417.08 million, a PE ratio of -3.35 and a beta of 0.58. The company has a debt-to-equity ratio of 1.88, a quick ratio of 3.41 and a current ratio of 3.47.

Institutional Investors Weigh In On Travere Therapeutics

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Armistice Capital LLC increased its position in shares of Travere Therapeutics by 0.7% during the third quarter. Armistice Capital LLC now owns 7,500,000 shares of the company’s stock worth $67,050,000 after acquiring an additional 50,000 shares in the last quarter. Vanguard Group Inc. grew its stake in shares of Travere Therapeutics by 10.9% during the 3rd quarter. Vanguard Group Inc. now owns 4,667,458 shares of the company’s stock valued at $41,727,000 after acquiring an additional 460,176 shares during the period. Kynam Capital Management LP increased its stake in shares of Travere Therapeutics by 105.6% during the fourth quarter. Kynam Capital Management LP now owns 2,000,000 shares of the company’s stock valued at $17,980,000 after buying an additional 1,027,398 shares during the period. Jacobs Levy Equity Management Inc. raised its stake in shares of Travere Therapeutics by 9.6% in the third quarter. Jacobs Levy Equity Management Inc. now owns 1,671,770 shares of the company’s stock worth $14,946,000 after purchasing an additional 146,970 shares during the last quarter. Finally, Finepoint Capital LP grew its holdings in Travere Therapeutics by 60.2% in the 4th quarter. Finepoint Capital LP now owns 1,435,321 shares of the company’s stock valued at $12,904,000 after buying an additional 539,500 shares in the last quarter.

Insider Buying and Selling at Travere Therapeutics

In related news, insider Peter Heerma sold 4,195 shares of the business’s stock in a transaction on Thursday, February 1st. The shares were sold at an average price of $8.53, for a total value of $35,783.35. Following the completion of the sale, the insider now directly owns 99,503 shares of the company’s stock, valued at $848,760.59. The sale was disclosed in a filing with the SEC, which is available through this hyperlink. In other news, CFO Christopher R. Cline sold 3,818 shares of Travere Therapeutics stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total value of $32,567.54. Following the sale, the chief financial officer now directly owns 70,903 shares in the company, valued at approximately $604,802.59. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Peter Heerma sold 4,195 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The stock was sold at an average price of $8.53, for a total value of $35,783.35. Following the sale, the insider now directly owns 99,503 shares of the company’s stock, valued at $848,760.59. The disclosure for this sale can be found here. Insiders sold 34,773 shares of company stock worth $300,625 over the last 90 days. Company insiders own 3.75% of the company’s stock.

About Travere Therapeutics

Travere Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and delivers therapies to people living with rare kidney and metabolic diseases. Its products include FILSPARI (sparsentan), a once-daily, oral medication designed to target two critical pathways in the disease progression of IgA Nephropathy (endothelin 1 and angiotensin-II); and Thiola and Thiola EC (tiopronin tablets) for the treatment of cystinuria, a rare genetic cystine transport disorder that causes high cystine levels in the urine and the formation of recurring kidney stones.